Composition for treatment of nicotine addiction containing a nicotine receptor antagonist and an anti-depressant of anti-anxiety drug

A technology for antidepressants and anti-anxiety drugs, applied in the direction of drug combinations, medical preparations containing active ingredients, active ingredients of heterocyclic compounds, etc.

Inactive Publication Date: 2001-01-17
CARY PHARMA
View PDF20 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the use of nicotine antagonists in combination with antidepressants or anxiolytics for the treatment of smoking cessation or for the treatment of other substance addictions has not been indicated before

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0064] The formulations containing about 1.0 mg of mecamylamine and about 50 mg of bupropion are combined into single tablets or capsules, and administered orally, 1 to 6 tablets per day.

Embodiment 2

[0066] The formulations containing about 1.0 mg of mecamylamine and about 150 mg of bupropion are combined into single tablets or capsules, and administered orally, 1 to 6 tablets per day.

Embodiment 3

[0068] The formulations containing about 5 mg of mecamylamine and about 50 mg of bupropion are combined into single tablets or capsules, and administered orally, 1 to 6 tablets per day.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention encompasses methods of treating patients for tobacco addiction and nicotine addiction, for palliating the effects of nicotine withdrawal, for providing or facilitating the effects of smoking cessation therapies and as long-term smoking cessation maintenance therapy. The invention also includes related pharmaceutical compositions comprising nicotine receptor antagonists and either an anti-depressant or an anti-anxiety drug. Specific combinations of drugs (mecamylamine HCl and bupropion HCl) as well as mecamylamine in combination with certain drug classes (e.g., anti-anxiety drugs and anti-depressants) comprise the pharmaceutical compositions disclosed. These compositions are also contemplated for use in the treatment of cocaine addiction and the treatment of alcohol dependence.

Description

field of invention [0001] The present invention relates to pharmaceutical compositions and methods of using these compositions to treat tobacco and nicotine addiction in patients, alleviate nicotine withdrawal effects, and enhance the effects of other smoking cessation treatments. Each of the substances in the disclosed pharmaceutical compositions has a unique mechanism of action, and when administered simultaneously, the combined agents provide unexpected effects over existing therapies. Background of the invention [0002] Tobacco addiction is the most important preventable cause of disease and death in today's society, killing more than 400,000 people every year. Currently, 1 in 5 Americans smokes, representing 50 million smokers in the United States alone. Half of all smokers will die from diseases directly related to tobacco use, and many smokers have significantly higher morbidity rates. About 15 million smokers try to quit each year, but only 1 million of them succe...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/135A61K31/505A61K31/55A61K45/06A61P25/32A61P25/34A61P25/36
CPCA61K31/135Y10S514/812Y10S514/811Y10S514/813A61K45/06A61P25/32A61P25/34A61P25/36A61K31/13A61K2300/00
Inventor D·D·卡里
Owner CARY PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap